ESLA
Estrella Biopharma Inc

291
Loading...
Loading...
News
all
press releases
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.
Stocktwits·6mo ago
News Placeholder
More News
News Placeholder
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (Estrella or the Company), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies to treat cancer and...
Business Wire·7mo ago
News Placeholder
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (Estrella or the Company), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...
Business Wire·7mo ago
News Placeholder
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells
Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (Estrella or the Company), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...
Business Wire·11mo ago
News Placeholder
Estrella Immunopharma Welcomes New Chairperson, Expands Board
The latest announcement is out from Estrella Immunopharma (ESLA). Estrella Immunopharma, Inc. has appointed Ms. Hong Zhang as the new Chairperson a...
TipRanks Financial Blog·1y ago
News Placeholder
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ('Estrella', Estrella Immunopharma, or the 'Company'), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted...
Business Wire·1y ago
News Placeholder
12 titres de soins de sant en mouvement lors de la session apr s-cl ture le 08/03/2024
Gagnants L'action Genelux (NASDAQ:GNLX) a mont vendredi de 10,06% 7 dollars lors de la session after-market. L'action Telesis Bio (NASDAQ:TBIO) a mont de 9,28% 0,60 dollars. Le titre Estrella...
Benzinga·1y ago

Latest ESLA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.